{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:55:53Z","timestamp":1790934953765,"version":"4.1.0"},"reference-count":159,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Typhoid fever, caused by Salmonella enterica serovars Typhi and Paratyphi, remains a major public health threat across Africa and Asia and causes substantial annual morbidity. Transmission persists in low- and middle-income countries (LMICs), where access to safe water and sanitation is limited. While improvements in water, sanitation, and hygiene (WASH) are essential, slow implementation makes vaccination the most practical preventive strategy. Current licensed vaccines have limitations, including suboptimal immune coverage in infants, limited duration of protection, and cold-chain requirements. This review examines bacteriophage-based vaccine platforms as emerging preclinical strategies for typhoid prevention. Phage technologies, including phage display, phage DNA, and hybrid models, offer potential advantages such as multivalent antigen display, projected thermostability, and cost-efficient production using bacterial manufacturing systems. Based on animal immunogenicity and proof-of-concept studies, these systems could theoretically induce durable immunity and broaden age-group protection, although their clinical feasibility and scalability remain unproven. We evaluate key technical hurdles, including endotoxin contamination, host-strain engineering, and payload-expression constraints. We also discuss how these potentially low-cost platforms may contribute to global antimicrobial resistance (AMR) mitigation efforts. Although phage-based vaccines remain in the preclinical stage, they represent promising research platforms for advancing vaccine equity and infectious disease resilience, provided regulatory and technical challenges are overcome. However, significant translational gaps must still be bridged before clinical application can be realized.<\/jats:p>","DOI":"10.3390\/vaccines14100869","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:10:48Z","timestamp":1790932248000},"page":"869","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phage-Based Vaccine Platforms for Typhoid Fever: A Transformative Approach to Global Health and Antimicrobial Resistance"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9060-990X","authenticated-orcid":false,"given":"Tambe David","family":"Tipah","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Natural and Applied Sciences, Plateau State University, Bokkos 932112, Plateau State, Nigeria"},{"name":"Center for Phage Biology and Therapeutics (CENPBAT) LTD\/GTE, Jos 930105, Plateau State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8424-4859","authenticated-orcid":false,"given":"Nnaemeka Emmanuel","family":"Nnadi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Natural and Applied Sciences, Plateau State University, Bokkos 932112, Plateau State, Nigeria"},{"name":"Center for Phage Biology and Therapeutics (CENPBAT) LTD\/GTE, Jos 930105, Plateau State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9738-1978","authenticated-orcid":false,"given":"Roderick A.","family":"Slavcev","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Waterloo, 10A Victoria St S, Kitchener, ON N2G 1C5, Canada"},{"name":"Theraphage, 151 Charles St W Suite # 199, Kitchener, ON N2G 1H6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wang, K., and Zhang, S. (2026). Global Trends, Inequalities, and Projections of Typhoid Fever Burden Among Children and Adolescents, 1990\u20132045: A Global Burden of Disease 2021 Analysis with a Focus on South Asia. Foodborne Pathog. Dis., 23.","DOI":"10.1177\/15353141261466560"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/14760584.2017.1255553","article-title":"The unrecognized burden of typhoid fever","volume":"16","author":"Obaro","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/cid\/ciaa504","article-title":"Review on the recent advances on typhoid vaccine development and challenges ahead","volume":"71","author":"Syed","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","first-page":"1","article-title":"The burden of typhoid fever in sub-Saharan Africa: A perspective","volume":"14","author":"Kim","year":"2022","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1473-3099(25)00551-1","article-title":"Complications and mortality of typhoid fever: An updated global systematic review and meta-analysis","volume":"26","author":"Murthy","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/ofid\/ofad120","article-title":"Diagnostics for typhoid fever: Current perspectives and future outlooks for product development and access","volume":"10","author":"Sapkota","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Aremu, S.O., Oruye, M.L., Adamu, E.I., Vuetkung, N.M., Jonathan, D.A., Janjaro, A.G., Matthew, G., Adepoju, E.O., Jiji, P.J., and Gimba, P.L. (2025). Application of diagnostic network optimization [DNOs] to tackle antimicrobial resistance in Sub-Saharan Africa. Discov. Public Health, 22.","DOI":"10.1186\/s12982-025-00689-1"},{"key":"ref_8","unstructured":"Debellut, F. (2026, July 22). Typhoid Is Costly for Families and Health Systems. Available online: https:\/\/www.coalitionagainsttyphoid.org\/typhoid-is-costly-for-families-and-health-systems\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.62746\/njlhs.v3n2.58","article-title":"Antibiotic resistance: Targeting extensively drug resistant (XDR) Salmonella typhi","volume":"3","author":"Ahmad","year":"2024","journal-title":"Natl. J. Life Health Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Britto, C.D., Wong, V.K., Dougan, G., and Pollard, A.J. (2018). A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Neglected Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006779"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1021\/acsinfecdis.0c00044","article-title":"The antibacterial research and development pipeline needs urgent solutions","volume":"6","author":"Beyer","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.copbio.2021.02.009","article-title":"Approaches for manufacture, formulation, targeted delivery and controlled release of phage-based therapeutics","volume":"68","author":"Malik","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AEM.03357-13","article-title":"Amplification and purification of T4-like Escherichia coli phages for phage therapy: From laboratory to pilot scale","volume":"80","author":"Bourdin","year":"2014","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mancuso, F., Shi, J., and Malik, D.J. (2018). High throughput manufacturing of bacteriophages using continuous stirred tank bioreactors connected in series to ensure optimum host bacteria physiology for phage production. Viruses, 10.","DOI":"10.3390\/v10100537"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/B978-0-12-394621-8.00018-2","article-title":"Structure, assembly, and DNA packaging of the bacteriophage T4 head","volume":"Volume 82","author":"Black","year":"2012","journal-title":"Advances in Virus Research"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1021\/acssynbio.2c00244","article-title":"SpyPhage: A cell-free TXTL platform for rapid engineering of targeted phage therapies","volume":"11","author":"Liyanagedera","year":"2022","journal-title":"ACS Synth. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Garenne, D., Bowden, S., and Noireaux, V. (2021). Cell-free expression and synthesis of viruses and bacteriophages: Applications to medicine and nanotechnology. Curr. Opin. Syst. Biol., 28.","DOI":"10.1016\/j.coisb.2021.100373"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/acs.bioconjchem.1c00018","article-title":"Bacteriophage capsid modification by genetic and chemical methods","volume":"32","author":"Carmody","year":"2021","journal-title":"Bioconjugate Chem."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stone, N.P., Demo, G., Agnello, E., and Kelch, B.A. (2019). Principles for enhancing virus capsid capacity and stability from a thermophilic virus capsid structure. Nat. Commun., 10.","DOI":"10.1038\/s41467-019-12341-z"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tao, P., Mahalingam, M., Zhu, J., Moayeri, M., Sha, J., Lawrence, W.S., Leppla, S.H., Chopra, A.K., and Rao, V.B. (2018). A bacteriophage T4 nanoparticle-based dual vaccine against anthrax and plague. mBio, 9.","DOI":"10.1128\/mBio.01926-18"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, M., Chen, C., Wang, X., Guo, P., Feng, H., Zhang, X., Zhang, W., Gu, C., Zhu, J., and Wen, G. (2023). T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines. Antivir. Res., 217.","DOI":"10.1016\/j.antiviral.2023.105688"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zhu, J., Sha, J., Batra, H., Jain, S., Wu, X., Hendrix, E.K., Kilgore, P.B., Sun, K., Plante, K.S., and Plante, J.A. (2025). A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Dual COVID-19-Flu Mucosal Vaccines. Small Sci., 5.","DOI":"10.1002\/smsc.202400580"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhao, G., Zhang, S., Zhang, Y., Jiao, S., Zeng, X., Zhao, L., Wang, J., Ma, J., Cheng, Y., and Wang, H. (2026). Preclinical Evaluation of a Phage T4-Based Multi-Epitope Nanoparticle Vaccine Against Porcine Epidemic Diarrhea Virus. Transbound. Emerg. Dis., 2026.","DOI":"10.1155\/tbed\/8438783"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zong, X., Ni, S., Chen, G., Li, X., Liu, J., Tong, Z., Yuan, Z., Jiang, S., Chen, H., and Tan, C. (2026). Immune Protection Effect of an OmpC-Recombinant T4 Bacteriophage Vaccine Against Infection Caused by Extraintestinal Pathogenic Escherichia coli in Mice. Vaccines, 14.","DOI":"10.3390\/vaccines14050383"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vetimm.2003.12.009","article-title":"Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis","volume":"99","author":"Manoutcharian","year":"2004","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.vaccine.2008.03.042","article-title":"Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis","volume":"26","author":"Morales","year":"2008","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1021\/acsinfecdis.6c00464","article-title":"A Modular T4 Phage-Based Nanoparticle Displaying Multiepitopes Provides Cross-Serotype Protection against Streptococcus suis in Mice and Swine","volume":"12","author":"Chen","year":"2026","journal-title":"ACS Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Buzil\u0103, E.R., Dorneanu, O.S., Trofin, F., Sima, C.M., and Iancu, L.S. (2025). Assessing Salmonella Typhi Pathogenicity and Prevention: The Crucial Role of Vaccination in Combating Typhoid Fever. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26093981"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Okesanya, O.J., Eshun, G., Ukoaka, B.M., Manirambona, E., Olabode, O.N., Adesola, R.O., Okon, I.I., Jamil, S., Singh, A., and Lucero-Prisno, D.E. (2024). Water, sanitation, and hygiene (WASH) practices in Africa: Exploring the effects on public health and sustainable development plans. Trop. Med. Health, 52.","DOI":"10.1186\/s41182-024-00614-3"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa0807521","article-title":"A cluster-randomized effectiveness trial of Vi typhoid vaccine in India","volume":"361","author":"Sur","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Paganotti Vicentine, M., McCann, N., Hennigan, O., Maria, N., Juarez Molina, C.I., Koleva, S., Islam, M.K., Jones, E., Flaxman, A., and Day, N. (2026). Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: Study protocol. BMJ Open, 16.","DOI":"10.1136\/bmjopen-2025-107608"},{"key":"ref_32","first-page":"e395","article-title":"8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): A prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial","volume":"14","author":"Pant","year":"2026","journal-title":"Lancet Glob. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1038\/s41591-025-04003-z","article-title":"A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: A randomized, placebo-controlled phase 1 trial","volume":"31","author":"Chen","year":"2025","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(23)02031-7","article-title":"Efficacy of typhoid conjugate vaccine: Final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children","volume":"403","author":"Patel","year":"2024","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0264-410X(99)00231-5","article-title":"Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine","volume":"17","author":"Levine","year":"1999","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Galen, J.E., Buskirk, A.D., Tennant, S.M., and Pasetti, M.F. (2016). Live attenuated human Salmonella vaccine candidates: Tracking the pathogen in natural infection and stimulation of host immunity. EcoSal Plus, 7.","DOI":"10.1128\/ecosalplus.esp-0010-2016"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijmm.2008.09.003","article-title":"Genetic stability of vaccine strain Salmonella Typhi Ty21a over 25 years","volume":"299","author":"Kopecko","year":"2009","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Riekkinen, M., Terrinoni, M., Pakkanen, S.H., Kaim, J., Vahlberg, T., Lundgren, A., and Kantele, A. (2026). Co-administration of oral killed whole-cell recombinant cholera toxin B-subunit vaccine (WC-rCTB) and live Salmonella Typhi Ty21a vaccine: A prospective randomized open-label trial. J. Travel Med., 33.","DOI":"10.1093\/jtm\/taag008"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/infdis\/jiw030","article-title":"Oral typhoid vaccination with live-attenuated Salmonella typhi strain Ty21a generates Ty21a-responsive and heterologous influenza virus\u2013responsive CD4+ and CD8+ T cells at the human intestinal mucosa","volume":"213","author":"Pennington","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/CVI.00058-12","article-title":"Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans","volume":"19","author":"Wahid","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Darton, T.C., Jones, C., Blohmke, C.J., Waddington, C.S., Zhou, L., Peters, A., Haworth, K., Sie, R., Green, C.A., and Jeppesen, C.A. (2016). Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Neglected Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004926"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0140-6736(91)91910-M","article-title":"Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine","volume":"338","author":"Simanjuntak","year":"1991","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Anwar, E., Goldberg, E., Fraser, A., Acosta, C.J., Paul, M., and Leibovici, L. (2014). Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev., 2014.","DOI":"10.1002\/14651858.CD001261.pub3"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ellis, G., and Decker, C.F. (2026). Typhoid vaccine. Disease-a-Month, 72.","DOI":"10.1016\/j.disamonth.2026.102120"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","unstructured":"World Health Organization (2026). Position paper on typhoid vaccines, 2026. Wkly. Epidemiol. Rec., 101, 166\u2013180. Available online: https:\/\/iris.who.int\/handle\/10665\/386927."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/CVI.00791-13","article-title":"Immune responses to Vi capsular polysaccharide typhoid vaccine in children 2 to 16 years old in Karachi, Pakistan, and Kolkata, India","volume":"21","author":"Ochiai","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4049\/immunohorizons.2300085","article-title":"TLR4 ligands in typhoid vi polysaccharide subunit vaccines contribute to immunogenicity","volume":"8","author":"Alugupalli","year":"2024","journal-title":"ImmunoHorizons"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Jossi, S.E., Arcuri, M., Alshayea, A., Persaud, R.R., Marcial-Ju\u00e1rez, E., Palmieri, E., Di Benedetto, R., P\u00e9rez-Toledo, M., Pillaye, J., and Channell, W.M. (2023). Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1139329"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zhu, H., Chelysheva, I., Cross, D.L., Blackwell, L., Jin, C., Gibani, M.M., Jones, E., Hill, J., Tr\u00fcck, J., and Kelly, D.F. (2023). Molecular correlates of vaccine-induced protection against typhoid fever. J. Clin. Investig., 133.","DOI":"10.1172\/JCI169676"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/polysaccharides2030042","article-title":"Polysaccharide vaccines: A perspective on non-typhoidal Salmonella","volume":"2","author":"Perera","year":"2021","journal-title":"Polysaccharides"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"C55","DOI":"10.1016\/j.vaccine.2015.04.028","article-title":"Typhoid fever vaccination strategies","volume":"33","author":"Date","year":"2015","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"key":"ref_54","unstructured":"Van Camp, R.O., and Shorman, M. (2026, August 27). Typhoid Vaccine, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470571\/."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhang, F., Thompson, C., Ma, N., Lu, Y.J., and Malley, R. (2022). Carrier Proteins Facilitate the Generation of Antipolysaccharide Immunity via Multiple Mechanisms. mBio, 13.","DOI":"10.1128\/mbio.03790-21"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/cid\/cix1145","article-title":"Seroefficacy of Vi polysaccharide\u2013tetanus toxoid typhoid conjugate vaccine (Typbar TCV)","volume":"67","author":"Voysey","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S1473-3099(25)00730-3","article-title":"Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: A phase 1 randomised controlled trial","volume":"26","author":"AbdelGhany","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1473-3099(21)00455-2","article-title":"Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: An observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial","volume":"22","author":"Saluja","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: Final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/cid\/ciy1103","article-title":"Typhoid Vaccine Acceleration Consortium Malawi: A phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi","volume":"68","author":"Meiring","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Medise, B.E., Windiani, I.G.A.T., Husada, D., Sekartini, R., Gunardi, H., Wirahmadi, A., Puspitasari, D., Kartina, L., Adnyana, I.G.A.N.S., and Sidiartha, I.G.L. (2025). One-month evaluation of safety and immunogenicity of a Vi-DT typhoid conjugate vaccine (Bio-TCV\u00ae) in Indonesian subjects 6 months to 45 years: A phase III randomized clinical trial. Vaccine X, 25.","DOI":"10.1016\/j.jvacx.2025.100661"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1016\/S2214-109X(21)00255-2","article-title":"Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: A cohort study","volume":"9","author":"Yousafzai","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gloeck, N.R., Leong, T., Iwu-Jaja, C.J., Katoto, P.D.M., Kredo, T., and Wiysonge, C.S. (2023). Typhoid conjugate vaccines for preventing typhoid fever (enteric fever). Cochrane Database Syst. Rev., 2023.","DOI":"10.1002\/14651858.CD015746"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e2122","DOI":"10.1016\/S2214-109X(25)00330-4","article-title":"Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: A multicentre, observer-blind, randomised, phase 3 study","volume":"13","author":"Ndiaye","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: Results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Van Damme, P., Kafeja, F., Anemona, A., Basile, V., Hilbert, A.K., De Coster, I., Forni, S., Sil, A., Sclavo, S., and Podda, A. (2011). Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: Randomized clinical testing in healthy adults. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025398"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.vaccine.2021.03.089","article-title":"An open-label, comparative, single dose, clinical Phase I study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults","volume":"39","author":"Choi","year":"2021","journal-title":"Vaccine"},{"key":"ref_68","unstructured":"World Health Organization (2026, August 27). WHO Recommends Use of First Typhoid Conjugate Vaccine. Available online: https:\/\/www.who.int\/news\/item\/03-04-2018-who-recommends-use-of-first-typhoid-conjugate-vaccine."},{"key":"ref_69","unstructured":"World Health Organization (2021). Comparison Table of WHO Prequalified Typhoid Conjugate Vaccines (TCVs), World Health Organization. Available online: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/10dee365-0868-4804-aa95-4d5435ab1425\/content."},{"key":"ref_70","unstructured":"Szu, S. (2026, August 27). Protein and Polysaccharide Conjugate Vaccines to Enteric Diseases. Food Safety Research Projects Database, National Agricultural Library, U.S. Department of Agriculture, 2012; Project Number: 1ZIAHD001308-28, Available online: https:\/\/www.nal.usda.gov\/research-tools\/food-safety-research-projects\/protein-and-polysaccharide-conjugate-vaccines-1."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJM200310023491423","article-title":"Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children","volume":"349","author":"Lanh","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1016\/j.vaccine.2020.03.028","article-title":"Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan","volume":"38","author":"Qamar","year":"2020","journal-title":"Vaccine"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gao, F., Lockyer, K., Logan, A., Davis, S., Bolgiano, B., Rijpkema, S., Singh, G., Prasad, S.D., Dondapati, S.P., and Sounkhla, G.S. (2021). Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate Vaccines. Microorganisms, 9.","DOI":"10.3390\/microorganisms9081707"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.vaccine.2004.11.044","article-title":"Policymakers\u2019 views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia","volume":"23","author":"DeRoeck","year":"2005","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1016\/j.vaccine.2016.09.036","article-title":"Funding gap for immunization across 94 low- and middle-income countries","volume":"34","author":"Ozawa","year":"2016","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1093\/cid\/ciaa1429","article-title":"Can Existing Improvements of Water, Sanitation, and Hygiene (WASH) in Urban Slums Reduce the Burden of Typhoid Fever in These Settings?","volume":"72","author":"Im","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","first-page":"37","article-title":"Barriers to typhoid fever vaccine access in endemic countries","volume":"8","author":"Khan","year":"2017","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: A randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The Efficacy of a Salmonella typhi Vi Conjugate Vaccine in Two-to-Five-Year-Old Children","volume":"344","author":"Lin","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wang, H., Yang, Y., Xu, Y., Chen, Y., Zhang, W., Liu, T., Chen, G., and Wang, K. (2024). Phage-based delivery systems: Engineering, applications, and challenges in nanomedicines. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-02576-4"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Zhou, G., Zhang, J., Zhang, Z., Cao, S., and Li, Y. (2026). M13 phage-based antigen presentation and immune response activation in vaccine development for animal infectious diseases. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1882961"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Hasani, S.M., Ghafouri, E., Kouhpayeh, S., Amerizadeh, F., Rahimmanesh, I., Amirkhani, Z., and Khanahmad, H. (2023). Phage based vaccine: A novel strategy in prevention and treatment. Heliyon, 9.","DOI":"10.1016\/j.heliyon.2023.e19925"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Venkataraman, S., Shahgolzari, M., Yavari, A., and Hefferon, K. (2025). Bacteriophages as targeted therapeutic vehicles: Challenges and opportunities. Bioengineering, 12.","DOI":"10.3390\/bioengineering12050469"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Harper, D.R., Abedon, S.T., Burrowes, B.H., and McConville, M.L. (2021). Phage Display Technology and the Development of Phage-Based Vaccines. Bacteriophages: Biology, Technology, Therapy, Springer.","DOI":"10.1007\/978-3-319-41986-2"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"15953","DOI":"10.1002\/chem.202002401","article-title":"Syntheses of Salmonella Paratyphi A associated oligosaccharide antigens and development towards anti-paratyphoid fever vaccines","volume":"26","author":"Dhara","year":"2020","journal-title":"Chem.\u2013A Eur. J."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Nooraei, S., Hajizade, A., Tarrahimofrad, H., Khatami, S., Shamsara, M., and Ahmadian, G. (2026). Design and structural characterization of a chimeric protein displayed on virus-like particles for targeted immune activation against Salmonella Typhi. Int. J. Biol. Macromol., 285.","DOI":"10.1016\/j.ijbiomac.2026.150913"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Wong, Z.W., and Yang, D. (2025). Disassembly and reassembly of AP205 virus-like particles and the removal of bound RNA for cargo encapsulation. Int. J. Biol. Macromol., 315.","DOI":"10.1016\/j.ijbiomac.2025.144641"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/ofid\/ofad041","article-title":"Salmonella combination vaccines: Moving beyond typhoid","volume":"10","author":"MacLennan","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/cmi.2008.11","article-title":"Salmonella typhi: From a human pathogen to a vaccine vector","volume":"5","author":"Zhang","year":"2008","journal-title":"Cell. Mol. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Xiong, K., Zhu, C., Chen, Z., Zheng, C., Tan, Y., Rao, X., and Cong, Y. (2017). Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi. Front. Cell. Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00135"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Beikzadeh, B. (2023). Immunoinformatics design of multi-epitope vaccine using OmpA, OmpD and enterotoxin against non-typhoidal salmonellosis. BMC Bioinform., 24.","DOI":"10.1186\/s12859-023-05183-6"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ghadi, F.E., Roudbari, Z., and Razavi, R. (2023). Designing of Multi-Epitope Peptide Vaccine Based on Outer Membrane Proteins OmpF, OmpC, and PgtE of Salmonella enterica Typhi. Arch. Razi Inst., 78.","DOI":"10.22541\/au.167343394.46753601\/v1"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hajam, I.A., Dar, P.A., Shahnawaz, I., Jaume, J.C., and Lee, J.H. (2017). Bacterial flagellin\u2014A potent immunomodulatory agent. Exp. Mol. Med., 49.","DOI":"10.1038\/emm.2017.172"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/imm.70001","article-title":"Flagellins as vaccine adjuvants and cancer immunotherapy: Recent advances and future prospects","volume":"176","author":"Talukder","year":"2025","journal-title":"Immunology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.azn.2025.09.001","article-title":"Flagellin: A crucial virulence factor coordinating bacterial pathogenesis and host immune responses","volume":"2","author":"Xia","year":"2026","journal-title":"Anim. Zoonoses"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Cao, M., Li, Y., Song, X., Lu, Z., Zhai, H., Qiu, H.-J., and Sun, Y. (2025). Broad-spectrum vaccines against various and evolving viruses: From antigen design to nanoparticle delivery. J. Virol., 99.","DOI":"10.1128\/jvi.00997-25"},{"key":"ref_97","unstructured":"Shariq, M., Hasnain, S.E., and Gupta, M.N. (2026). Unraveling Mycobacterium tuberculosis pathogenesis: Insights into PE\/PPE proteins from a molecular viewpoint. Navigating Tuberculosis: Insights Into Host-Pathogen Protein Interactions, Academic Press."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jaroszewicz, W., Morcinek-Or\u0142owska, J., Pierzynowska, K., Gaffke, L., and W\u0119grzyn, G. (2022). Phage display and other peptide display technologies. FEMS Microbiol. Rev., 46.","DOI":"10.1093\/femsre\/fuab052"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.3390\/ijms13045179","article-title":"Filamentous bacteriophage fd as an antigen delivery system in vaccination","volume":"13","author":"Prisco","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Asar, M., Newton-Northup, J., and Soendergaard, M. (2024). Improving pharmacokinetics of peptides using phage display. Viruses, 16.","DOI":"10.3390\/v16040570"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ragothaman, M., and Yoo, S.Y. (2023). Engineered phage-based cancer vaccines: Current advances and future directions. Vaccines, 11.","DOI":"10.3390\/vaccines11050919"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Mora, A., Hern\u00e1ndez-P\u00e9rez, J., Iqbal, H.M., Rito-Palomares, M., and Benavides, J. (2020). Bacteriophage-based vaccines: A potent approach for antigen delivery. Vaccines, 8.","DOI":"10.3390\/vaccines8030504"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Tao, P., Mahalingam, M., Kirtley, M.L., van Lier, C.J., Sha, J., Yeager, L.A., Chopra, A.K., and Rao, V.B. (2013). Mutated and Bacteriophage T4 Nanoparticle Arrayed F1-V Immunogens from Yersinia pestis as Next Generation Plague Vaccines. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003495"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/78490","article-title":"Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses","volume":"18","author":"Sartorius","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Hietala, V., Horsma-Heikkinen, J., Carron, A., Skurnik, M., and Kiljunen, S. (2019). The Removal of Endo- and Enterotoxins From Bacteriophage Preparations. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01674"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Cross, A.S. (2023). Hit \u2019em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target. Microbiol. Mol. Biol. Rev., 87.","DOI":"10.1128\/mmbr.00045-22"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Ongkudon, C.M., Chew, J.H., Liu, B., and Danquah, M.K. (2012). Chromatographic Removal of Endotoxins: A Bioprocess Engineer\u2019s Perspective. Int. Sch. Res. Not., 2012.","DOI":"10.5402\/2012\/649746"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1002\/bit.27362","article-title":"Current technologies to endotoxin detection and removal for biopharmaceutical purification","volume":"117","author":"Schneier","year":"2020","journal-title":"Biotechnol. Bioeng."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Alt\u0131nta\u015f, \u00d6., B\u00fclb\u00fcl, A., Safran, V., Y\u0131lmaz, F., and Denizli, A. (2026). Smart polymeric platforms for endotoxin removal from biopharmaceuticals: Advanced architectures, design strategies and applications. RSC Appl. Polym.","DOI":"10.1039\/D6LP00282J"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Bichet, M.C., Adderley, J., Avellaneda-Franco, L., Magnin-Bougma, I., Torriero-Smith, N., Gearing, L.J., Deffrasnes, C., David, C., Pepin, G., and Gantier, M.P. (2023). Mammalian cells internalize bacteriophages and use them as a resource to enhance cellular growth and survival. PLoS Biol., 21.","DOI":"10.1101\/2023.03.10.532157"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Dong, X., Pan, P., Ye, J.-J., Zhang, Q.-L., and Zhang, X.-Z. (2022). Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy. Biomaterials, 289.","DOI":"10.1016\/j.biomaterials.2022.121763"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Chen, F., Zhang, M., Yang, F., Wang, L., Liu, J., Liu, J., and Pang, Y. (2024). Dual-Antigen-Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications. Small, 20.","DOI":"10.1002\/smll.202307748"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ga, E., Kang, J.A., Hwang, J., Moon, S., Choi, J., Bae, E., Seol, H., Mun, Y., Song, D., and Jeong, D.G. (2024). Assessment of the immune interference effects of multivalent vaccine for influenza epidemic strain in 2022\u20132023 and evaluation of its efficacy. Heliyon, 10.","DOI":"10.1016\/j.heliyon.2024.e28326"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Zhang, T., Han, Y., Huang, W., Wei, H., Zhao, Y., Shu, L., Guo, Y., Ye, B., Zhou, J., and Liu, J. (2024). Neutralizing antibody responses against contemporary and future influenza A(H3N2) viruses in paradoxical clades elicited by repeated and single vaccinations. J. Med. Virol., 96.","DOI":"10.1002\/jmv.29743"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4161\/hv.27714","article-title":"Hybrid phage displaying SLAQVKYTSASSI induces protection against Candida albicans challenge in BALB\/c mice","volume":"10","author":"Wang","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cimid.2019.05.004","article-title":"Immunological properties of the SLLTEVET epitope of Influenza A virus in multiple displays on filamentous M13 phage","volume":"65","author":"Lotfi","year":"2019","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Chen, W., Peters, D.L., Lam, S., and Kettal, M. (2025). Bacteriophages as Vaccine Platforms: Opportunities and Challenges in Translation. Hum. Vaccines Immunother., 21.","DOI":"10.1080\/21645515.2025.2599632"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Setyo Utomo, D.I., Suhaimi, H., Muhammad Azami, N.A., Azmi, F., Mohd Amin, M.C.I., and Xu, J. (2023). An overview of recent developments in the application of antigen displaying vaccine platforms: Hints for future SARS-CoV-2 VLP vaccines. Vaccines, 11.","DOI":"10.3390\/vaccines11091506"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Palma, M. (2023). Aspects of Phage-Based Vaccines for Protein and Epitope Immunization. Vaccines, 11.","DOI":"10.3390\/vaccines11020436"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Gupta, R., Arora, K., Roy, S.S., Joseph, A., Rastogi, R., Arora, N.M., and Kundu, P.K. (2023). Platforms, Advances, and Technical Challenges in Virus-Like Particles-Based Vaccines. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1123805"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Kheirvari, M., Liu, H., and Tumban, E. (2023). Virus-like Particle Vaccines and Platforms for Vaccine Development. Viruses, 15.","DOI":"10.3390\/v15051109"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrmicro3525","article-title":"Outer-Membrane Vesicles from Gram-Negative Bacteria: Biogenesis and Functions","volume":"13","author":"Schwechheimer","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Dowling, D.J., Sanders, H., Cheng, W.K., Joshi, S., Brightman, S., Bergelson, I., Pietrasanta, C., van Haren, S.D., van Amsterdam, S., and Fernandez, J. (2016). A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00562"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Petousis-Harris, H., and Radcliff, F.J. (2019). Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00683"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Zhu, Z., Antenucci, F., Villumsen, K.R., and Bojesen, A.M. (2021). Bacterial Outer Membrane Vesicles as a Versatile Tool in Vaccine Research and the Fight against Antimicrobial Resistance. mBio, 12.","DOI":"10.1128\/mBio.01707-21"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"12728","DOI":"10.1039\/D6NR01038E","article-title":"Engineering Strategies of Bacterial Outer Membrane Vesicles for Enhancing Tumor Immunotherapy","volume":"18","author":"Yu","year":"2026","journal-title":"Nanoscale"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/biot.201400395","article-title":"Outer Membrane Vesicles as Platform Vaccine Technology","volume":"10","author":"Stork","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1007\/s00018-021-03842-6","article-title":"Nanoparticle-Based Approaches to Target the Lymphatic System for Antitumor Treatment","volume":"78","author":"Peng","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Liu, S., Lin, M., and Zhou, X. (2025). T4 phage displaying dual antigen clusters against H3N2 influenza virus infection. Vaccines, 13.","DOI":"10.3390\/vaccines13010070"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1007\/s00216-023-04606-w","article-title":"M13 phage: A versatile building block for a highly specific analysis platform","volume":"415","author":"Wang","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1021\/acssynbio.5c00450","article-title":"Computational Pipeline for Targeted Integration and Variable Payload Expression in Bacteriophage Engineering","volume":"14","author":"Fernbach","year":"2025","journal-title":"ACS Synth. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tibtech.2023.09.008","article-title":"Applications of Designer Phage Encoding Recombinant Gene Payloads","volume":"42","author":"Schmitt","year":"2024","journal-title":"Trends Biotechnol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1089\/dna.1988.7.735","article-title":"Lambda PMV: A Bacteriophage Vector Allowing Single-Step Retrieval of cDNAs Following Expression in Mammalian Cells","volume":"7","author":"DiSanto","year":"1988","journal-title":"DNA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/104454903321112451","article-title":"Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments","volume":"22","author":"Gaubin","year":"2003","journal-title":"DNA Cell Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"973","DOI":"10.15252\/emmm.201404525","article-title":"Antigen Delivery by Filamentous Bacteriophage fd Displaying an Anti-DEC-205 Single-Chain Variable Fragment Confers Adjuvanticity by Triggering a TLR9-Mediated Immune Response","volume":"7","author":"Sartorius","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.copbio.2020.11.002","article-title":"Phages in Vaccine Design and Immunity; Mechanisms and Mysteries","volume":"68","author":"Chen","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Mutti, M., and Corsini, L. (2019). Robust Approaches for the Production of Active Ingredient and Drug Product for Human Phage Therapy. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02289"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/bit.26911","article-title":"A scaled-down model for the translation of bacteriophage culture to manufacturing scale","volume":"116","author":"Ali","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Garc\u00eda, R., Latz, S., Romero, J., Higuera, G., Garc\u00eda, K., and Bast\u00edas, R. (2019). Bacteriophage production models: An overview. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01187"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Maxim Ward, J., Branston, S., Stanley, E., and Keshavarz-Moore, E. (2020). Scale-up and bioprocessing of phages. Bacteriophages\u2014Perspectives and Future, IntechOpen.","DOI":"10.5772\/intechopen.88275"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/153567601001500106","article-title":"Contained use of bacteriophages: Risk assessment and biosafety recommendations","volume":"15","author":"Verheust","year":"2010","journal-title":"Appl. Biosaf."},{"key":"ref_142","unstructured":"Regalla, D.K.R., and Porter, L. (2026, August 28). Bacteriophages, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493185\/."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Coxon, C., Bell, E., Adriaenssens, E., Clark, J., Edwards, J., Gohir, T., Hodges, F., Jones, J., Rees, C., and Sansom, A. (2025). Interpretation guidance for MHRA regulatory considerations for phage therapeutic products. Microbiology, 171.","DOI":"10.1099\/mic.0.001613"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Le, H.T., Ahlenstiel, G., Venturini, C., and Read, S.A. (2025). MGem: Immune recognition and clearance of bacteriophages\u2014Implications for phage therapy. mBio, 16.","DOI":"10.1128\/mbio.01418-25"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s100960050361","article-title":"Experience With Salmonella typhi Vi Capsular Polysaccharide Vaccine","volume":"18","author":"Hessel","year":"1999","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1016\/j.vaccine.2017.10.081","article-title":"Development of a synthetic Vi polysaccharide vaccine for typhoid fever","volume":"35","author":"Ni","year":"2017","journal-title":"Vaccine"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijid.2021.05.061","article-title":"Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial","volume":"108","author":"Sirima","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1093\/cid\/ciaa343","article-title":"Typhoid Conjugate Vaccines and Enteric Fever Control: Where to Next?","volume":"71","author":"Steele","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Thuluva, S., Paradkar, V., Matur, R., Turaga, K., and Gv, S.R. (2022). A multicenter, single-blind, randomized, phase-2\/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E\u2019s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEV\u2122) in healthy infants, children, and adults in comparison with a licensed comparator. Hum. Vaccines Immunother., 18.","DOI":"10.1080\/21645515.2022.2043103"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/159.4.766","article-title":"Comparative Efficacy of Two, Three, or Four Doses of TY21a Live Oral Typhoid Vaccine in Enteric-Coated Capsules: A Field Trial in an Endemic Area","volume":"159","author":"Ferreccio","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_151","unstructured":"Agarwal, M. (2006). Immunization for Children, Paras Medical Publisher."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(87)90480-6","article-title":"Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation","volume":"329","author":"Levine","year":"1987","journal-title":"Lancet"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/2326-6066.CIR-18-0179","article-title":"Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer","volume":"6","author":"Bartolacci","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Ghafouri, E., Fadaie, M., Amirkhani, Z., Esmaeilifallah, M., Rahimmanesh, I., Hosseini, N., Hejazi, H., and Khanahmad, H. (2024). Evaluation of humoral and cellular immune responses against Vibrio cholerae using oral immunization by multi-epitope-phage-based vaccine. Int. Immunopharmacol., 134.","DOI":"10.1016\/j.intimp.2024.112160"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2019.03.012","article-title":"Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer","volume":"166","author":"Zhai","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Yang, Y.-A., Chong, A., and Song, J. (2018). Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic Design. Vaccines, 6.","DOI":"10.3390\/vaccines6030045"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4161\/viru.21087","article-title":"Salmonella enterica Serovars Typhimurium and Typhi as Model Organisms: Revealing Paradigm of Host-Pathogen Interactions","volume":"3","author":"Garai","year":"2012","journal-title":"Virulence"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.coi.2013.05.012","article-title":"Humanized mice for the study of infectious diseases","volume":"25","author":"Brehm","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.chom.2010.09.003","article-title":"A Mouse Model for the Human Pathogen Salmonella Typhi","volume":"8","author":"Song","year":"2010","journal-title":"Cell Host Microbe"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/10\/869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:18:14Z","timestamp":1790932694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/10\/869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":159,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["vaccines14100869"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14100869","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}